MessageWhich begs the question: Why is the FDA not running this company out of business for advertising what CS can do?
----- Original Message ----- From: Jan Stoeten To: [email protected] Sent: Friday, February 27, 2004 10:22 AM Subject: Re: CS>5 days for Malaria http://www.silversolution.us/ Jan Stoeten, the Netherlands ----- Original Message ----- From: Medwith, Robert To: '[email protected]' Sent: Friday, February 27, 2004 4:03 PM Subject: RE: CS>5 days for Malaria What is ASAP Solution are they talking about CS Bob -----Original Message----- From: [email protected] [mailto:[email protected]] On Behalf Of William Meyer Sent: Friday, February 27, 2004 9:39 AM To: [email protected] Subject: Re: CS>5 days for Malaria what is notable here is that no mining company can profit from "homeopathic" silver. so, this has nothing to do with mining profits. it is a different idea. On Feb 27, 2004, at 8:25 AM, Ross Craig wrote: Clifton Mining Company - New Human Study Data Released ALPINE, UT, Feb. 27 /CNW/ - Clifton Mining Company (Clifton)(OTC:CFTN) American Biotech Labs (a private company in which Clifton, the largest shareholder is releasing new human study data on use of the ASAP Solution in west African hospitals, against a number of human ailments including malaria and a viral infections. New Human Studies American Biotech Labs (ABL) has been working in conjunction with four hospitals in West Africa that have been conducting human studies of the ASAP product as a antibiotic alternative against human ailments like malaria, fungal infections, ear infections, measles, septic ulcers and a number of serious viral problems. This is the second set of human studies released by the west African hospitals. The new studies found the product effective against all the above ailments. In conjunction with the human studies, the country of Ghana has approved the ASAP supplement product as a homeopathic drug. Malaria The past ASAP human malarial studies found the product effective in all of the cases averaging only five days of treatment to full recovery. This new study has taken the testing to a new level checking the blood of patients deemed fully recovered to see if any signs of the parasites remain in the bloodstream. According to the data in the studies, the patients showed absolutely no malarial protozoans left in the bloodstream. Over 900 million people are estimated to have this disease, many in poor countries. Said Keith Moeller, VP, "Evidence is steadily mounting that we may be able to help millions of people who are suffering from this disease. It is also exciting to see the first human studies in which the product is being used as a treatment for people who suffer from serious viral infections." Testing of the ASAP product continues in the African hospitals, as well as in numerous other facilities worldwide.
